ProPhase Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

ProPhase Labs şirketinin toplam hissedar öz sermayesi $38.1M ve toplam borcu $17.2M olup, bu da borç-öz sermaye oranını 45.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $91.8M ve $53.7M dir.

Anahtar bilgiler

45.1%

Borç/özkaynak oranı

US$17.18m

Borç

Faiz karşılama oranı	n/a
Nakit	US$503.00k
Eşitlik	US$38.13m
Toplam yükümlülükler	US$53.68m
Toplam varlıklar	US$91.81m

Son finansal sağlık güncellemeleri

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

Aug 11

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Jan 24

Recent updates

Investors Give ProPhase Labs, Inc. (NASDAQ:PRPH) Shares A 65% Hiding

Nov 09

It's Down 65% But ProPhase Labs, Inc. (NASDAQ:PRPH) Could Be Riskier Than It Looks

Nov 09

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Jul 03

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Mar 04

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Jan 09

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Sep 21

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

Aug 11

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Apr 07

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Jul 21

ProPhase Labs: A Stellar Quarter And Another Special Dividend

May 16

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PRPH 'nin kısa vadeli varlıkları ( $42.2M ) kısa vadeli yükümlülüklerini ( $28.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: PRPH şirketinin kısa vadeli varlıkları ( $42.2M ) uzun vadeli yükümlülüklerini ( $25.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PRPH 'nin net borç/öz sermaye oranı ( 43.7% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: PRPH şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 45.1% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PRPH son raporlanan serbest nakit akışına göre 0 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: PRPH serbest nakit akışı tahminlerine göre 0 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

ProPhase Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

ProPhase Labs, Inc. announced delayed 10-Q filing

ProPhase Labs Receives Non-Compliance Notice from Nasdaq Regarding Listing Rule 5605(c)(2)(A)

ProPhase Labs, Inc. announced delayed 10-Q filing

ProPhase Labs, Inc. announced delayed annual 10-K filing

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Recent updates

ProPhase Labs, Inc. announced delayed 10-Q filing

ProPhase Labs, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

ProPhase Labs, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Investors Give ProPhase Labs, Inc. (NASDAQ:PRPH) Shares A 65% Hiding

It's Down 65% But ProPhase Labs, Inc. (NASDAQ:PRPH) Could Be Riskier Than It Looks

ProPhase Labs, Inc. has completed a Follow-on Equity Offering in the amount of $3.0024 million.

Price target decreased by 7.5% to US$18.50

Insufficient new directors

ProPhase Labs, Inc. has completed a Follow-on Equity Offering in the amount of $3.0024 million.

ProPhase Labs Receives Non-Compliance Notice from Nasdaq Regarding Listing Rule 5605(c)(2)(A)

ProPhase Labs, Inc. announced delayed 10-Q filing

ProPhase Labs, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Price target decreased by 7.5% to US$18.50

Insufficient new directors

ProPhase Labs, Inc., Annual General Meeting, Jun 20, 2024

ProPhase Labs, Inc. to Report Q1, 2024 Results on May 09, 2024

ProPhase Labs, Inc. Unveils Project ZenQ-AI

ProPhase Labs, Inc. announced delayed annual 10-K filing

ProPhase Labs, Inc. to Report Fiscal Year 2023 Results on Mar 15, 2024

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Prophase Labs, Inc. Announces Important Developments in the Company’s Efforts to Commercialize Its Novel Be-Smart Esophageal Cancer Diagnostic Test

ProPhase Labs, Inc. Announces Preliminary Positive Results for Dietary Supplement Equivir

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Consensus revenue estimates fall by 16%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ProPhase Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Consensus EPS estimates fall by 46%

New minor risk - Market cap size

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

First quarter 2023 earnings released: EPS: US$0.033 (vs US$0.81 in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

ProPhase Labs, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Investor sentiment deteriorates as stock falls 17%

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

Consensus estimates of losses per share improve by 19%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs, Inc. to Report Q1, 2023 Results on May 11, 2023

Investor sentiment improves as stock rises 18%

Price target increased by 13% to US$17.00

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

ProPhase Labs, Inc. Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Chairman & CEO exercised options and sold US$2.0m worth of stock

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Chairman & CEO exercised options and sold US$2.8m worth of stock

ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million.

ProPhase Labs, Inc. Announces Executive Changes

ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million.

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% undervalued after recent price drop

ProPhase Labs, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Chairman & CEO exercised options and sold US$3.1m worth of stock

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

ProPhase Labs, Inc. Announces Resignation of Bill White as Chief Financial Officer

Consensus EPS estimates increase by 49%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs Q2 2022 Earnings Preview

ProPhase Labs, Inc. to Report Q2, 2022 Results on Aug 11, 2022

ProPhase Labs, Inc. (NasdaqCM:PRPH) announces an Equity Buyback for $6 million worth of its shares.

We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

Investor sentiment deteriorated over the past week

ProPhase Labs to license two investigational cancer compounds from Global BioLife